

RECEIVED
CENTRAL FAX CENTER

JAN 30 2007

Atty Docket No. 149 US UT01

FAX NO.: 571/273-8300

OFFICIAL COMMUNICATION FOR THE ATTENTION OF
THE U.S. PATENT AND TRADEMARK OFFICE
CERTIFICATION OF FACSIMILE TRANSMISSION


I hereby certify that the following documents in re Application of Naoya TSURUSHITA et al., Application No. 10/788,625, filed February 26, 2004, for HUMANIZED CHICKEN ANTIBODIES are being facsimile transmitted to the United States Patent and Trademark Office, on the date shown below.

Documents Attached

1. Transmittal Form PTO/SB/21 (1 page)
2. Copy of Notice of Non-Compliant Amendment (1 page)
3. Response to Notice under 37 C.F.R. §1.21 (4 pages)
4. Power of Attorney and Correspondence Address Form (2nd Submission – 1 page); and
5. Statement Under 37 C.F.R. §3.73(b) (2nd Submission – 1 page)

Number of pages being transmitted, including this page: 9

Dated: January 30, 2007


Tami Haskins

*PLEASE CONFIRM RECEIPT OF THIS PAPER BY
RETURN FACSIMILE AT (510) 574-1473*

PDL BIOPHARMA, INC.
Legal Department
34801 Campus Drive
Fremont, CA 94555
Telephone: 510/574-1400
Customer No.: 47470

RECEIVED
CENTRAL FAX CENTER

002

JAN 30 2007

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL
FORM

(to be used for all correspondence after initial filing)

		Application Number	10/788,625
		Filing Date	February 26, 2004
		First Named Inventor	Tsurushita et al.
		Art Unit	1643
		Examiner Name	David J. Blanchard
Total Number of Pages in This Submission	8	Attorney Docket Number	149 US UT01


ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Technology Center (TC)
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Response to Notice of Non-Compliant Amendment	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input checked="" type="checkbox"/> Copy of Notice	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input checked="" type="checkbox"/> Response w/ Complete Listing of Claims	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	Power of Attorney and Correspondence Address Indication Form with Statement under 3.73(b) – Second Submission
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s)	
<input type="checkbox"/> Certified Copy of Priority Document(s)		
<input type="checkbox"/> Response to Missing Parts/Incomplete Application		

Remarks


The Director is hereby authorized to charge any fee(s) or underpayments of fee(s) or credit any overpayments to PDL BioPharma, Inc. Deposit Account No. 50-3270 for the paper(s) submitted herewith.

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Firm or Individual name	Man Sung Co, Reg. No. 42,423, PDL BIOPHARMA, INC.
Signature	
Date	January 30, 2007

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO (Facsimile No. 571-273-8300) or deposited with the United States Postal Service with sufficient postage as Express mail (Label No.) in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on January 30, 2007.

Typed or printed name	Tami Haskins		
Signature		Date	January 30, 2007

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Notice of Non-Compliant Amendment (37 CFR 1.121)	Application No.	Applicant(s)	
	10/788625	Art Unit	
<p><i>-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --</i></p> <p>The amendment document filed on 1/20/06 is considered non-compliant because it has failed to meet the requirements of 37 CFR 1.121 or 1.4. In order for the amendment document to be compliant, correction of the following item(s) is required.</p> <p>THE FOLLOWING MARKED (X) ITEM(S) CAUSE THE AMENDMENT DOCUMENT TO BE NON-COMPLIANT:</p> <p><input checked="" type="checkbox"/> 1. Amendments to the specification:</p> <ul style="list-style-type: none"> <input type="checkbox"/> A. Amended paragraph(s) do not include markings. <input type="checkbox"/> B. New paragraph(s) should not be underlined. <input type="checkbox"/> C. Other _____. <p><input type="checkbox"/> 2. Abstract:</p> <ul style="list-style-type: none"> <input type="checkbox"/> A. Not presented on a separate sheet. 37 CFR 1.72. <input type="checkbox"/> B. Other _____. <p><input type="checkbox"/> 3. Amendments to the drawings:</p> <ul style="list-style-type: none"> <input type="checkbox"/> A. The drawings are not properly identified in the top margin as "Replacement Sheet," "New Sheet," or "Annotated Sheet" as required by 37 CFR 1.121(d). <input type="checkbox"/> B. The practice of submitting proposed drawing correction has been eliminated. Replacement drawings showing amended figures, without markings, in compliance with 37 CFR 1.84 are required. <input type="checkbox"/> C. Other _____. <p><input checked="" type="checkbox"/> 4. Amendments to the claims:</p> <ul style="list-style-type: none"> <input checked="" type="checkbox"/> A. A complete listing of all of the claims is not present. <input type="checkbox"/> B. The listing of claims does not include the text of all pending claims (including withdrawn claims). <input type="checkbox"/> C. Each claim has not been provided with the proper status identifier, and as such, the individual status of each claim cannot be identified. Note: the status of every claim must be indicated after its claim number by using one of the following status identifiers: (Original), (Currently amended), (Canceled), (Previously presented), (New), (Not entered), (Withdrawn) and (Withdrawn-currently amended). <input type="checkbox"/> D. The claims of this amendment paper have not been presented in ascending numerical order. <input type="checkbox"/> E. Other: _____. <p><input type="checkbox"/> 5. Other (e.g., the amendment is unsigned or not signed in accordance with 37 CFR 1.4):</p>			

For further explanation of the amendment format required by 37 CFR 1.121, see MPEP § 714.

TIME PERIODS FOR FILING A REPLY TO THIS NOTICE:

1. Applicant is given **no new time period** if the non-compliant amendment is an after-final amendment, an amendment filed after allowance, or a drawing submission (only). If applicant wishes to resubmit the non-compliant after-final amendment with corrections, the entire corrected amendment must be resubmitted.
2. Applicant is given **one month**, or thirty (30) days, whichever is longer, from the mail date of this notice to supply the correction, if the non-compliant amendment is one of the following: a preliminary amendment, a non-final amendment (including a submission for a request for continued examination (RCE) under 37 CFR 1.114), a supplemental amendment filed within a suspension period under 37 CFR 1.103(a) or (c), and an amendment filed in response to a Quayle action. If any of above boxes 1. to 4. are checked, the correction required is only the corrected section of the non-compliant amendment in compliance with 37 CFR 1.121.

Extensions of time are available under 37 CFR 1.136(a) only if the non-compliant amendment is a non-final amendment or an amendment filed in response to a Quayle action.

Failure to timely respond to this notice will result in:

Abandonment of the application if the non-compliant amendment is a non-final amendment or an amendment filed in response to a Quayle action; or

Non-entry of the amendment if the non-compliant amendment is a preliminary amendment or supplemental amendment.

571-272-0521

Legal Instruments Examiner (LIE), if applicable
U.S. Patent and Trademark Office
PTOL-324 (04-06)

Notice of Non-Compliant Amendment (37 CFR 1.121)

Telephone No.

Part of Paper No.